EPElizabeth Davida Paratz

Elizabeth Davida Paratz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth Davida Paratz has a total of 449 co-authors. Here are the top co-authors by number of shared publications:

  • Andre La Gerche

    Department of Cardiology, St Vincent's Hospital Melbourne, 41 Victoria Parade, Fitzroy, VIC 3065, Australia

    29 shared publications
  • Dion Stub

    Department of Cardiology, Alfred Hospital, 55 Commercial Rd, Prahran, VIC 3181, Australia

    23 shared publications
  • Andre La Gerche

    St Vincent's Institute of Medical Research

    18 shared publications
  • Andreas Pflaumer

    Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Grattan St, Parkville, VIC 3000, Australia

    15 shared publications
  • Christopher Semsarian

    Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, University of Sydney, Sydney, Australia

    15 shared publications
  • Dominica Zentner

    Murdoch Children's Research Institute, 50 Flemington Rd Parkville VIC 3052; Royal Melbourne Hospital, 400 Grattan St Parkville VIC 3000

    14 shared publications

Latest Publications

  • Open Access

    Psychosocial and survivorship care needs following young out-of-hospital sudden cardiac arrest: a rapid scoping review

    by Natalie Stewart, Rosalind Case, Jessica Finney, Lucas Mitchell, Ebony Richardson, Leesa Adlard, Elizabeth Paratz, Jamie Vandenberg, Janet Bray, Jodie Ingles, et al.

    Importance : Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) are significant public health issues globally. SCA incidence is highest among older adults, however occurrence among young individuals (<50 years) carries a disproportionate impact due to premature mortality, family burden, and economic impact. SCA occurring in a young person is more likely to be caused by inherited cardiovascular conditions, resulting in additional familial implications and profound psychosocial impacts. ‘Survivorship care’ refers to long-term, holistic care supporting a patient’s wellbeing, integrating cognitive, psychological, social and functional aspects of long-term recovery. Although survivorship care following SCA has been increasingly prioritized, the psychosocial care needs specific to young SCA/SCD populations have not been collectively reviewed to date. Objectives : We performed a rapid scoping review to synthesize evidence on survivorship care needs following young (<50 years) SCA and identify gaps to inform future intervention development. Evidence review : MEDLINE, Embase, PsycInfo and CINAHL were searched on 1 July 2025 and the search re-run on 12 July 2026 for peer-reviewed primary articles published since 2015. Eligible studies were those which reported care needs, or the psychosocial, cognitive, functional, informational, or survivorship-related outcomes. These were used to infer care needs among young SCA survivors, co-survivors, and SCD bereaved family members. Findings : Twenty studies met our inclusion criteria. Findings were related to both adult and pediatric survivors as well as bereaved family members; none of the included studies focused exclusively on co-survivors. Adult survivors commonly experience anxiety, depression, posttraumatic stress symptoms, cognitive impairment, impacted sense of self, and challenges returning to work, pointing to support needs in these areas. Pediatric survivors have persistent neurocognitive and adaptive functioning challenges, return to school difficulties and other ongoing support needs. Bereaved family members report psychological distress, prolonged grief, and unmet needs for counselling, peer support, timely information, and coordinated follow-up care. Conclusions and relevance : Young SCA/SCD may represent a distinct survivorship context characterized by life stage, family disruption, potential genetic risk, and different recovery trajectories. Our findings suggest a need for targeted research into survivorship care pathways that integrate psychosocial care into the young SCA/SCD context.

  • 10 Years of the National Echo Database of Australia (NEDA): A Nationwide Research Platform Designed for Collaboration

    by Elizabeth D. Paratz, Simon Stewart, Bronwyn Brown, Nerolie Stickland, Kai Chan, Alexander Chen, Gregory Scalia Am, Majo Joseph, Jim Codde, David Prior, et al.


  • Open Access

    The Creation of the Cardiac Society of Timor-Leste: A Major Step Forward in Timorese Cardiac Health

    by Elizabeth D. Paratz, Rachel Nunn, Jane Williams, Zoe Fitzgerald, Diana Marques, Sidonia Ximenes, Ricardo Flavio, Claudia Natalicia Magno, Jacinto da Costa Vinhas, Sidonio Viana, et al.

  • Open Access

    Acute Aortic Dissection Associated With Cancer Therapy in a Previously Normal Aorta

    by Simon A. Savage, Melissa Moore, Trevor Tnay, Elizabeth D. Paratz


  • Open Access

    Atrial Fibrillation Screening in Those with Rheumatic Heart Disease: A Narrative Policy Content Review

    by Elizabeth Paratz, Xinying Zhou, Caio A. M. Tavares, Priyansh Shah, Julian Hoevelmann, Menglu Ouyang, Diana H. P. Foo, Amitava Banerjee, Ben Freedman, James Marangou, et al.

    Rheumatic heart disease (RHD) and atrial fibrillation (AF) are major global health burdens. AF affects up to one-third of individuals with RHD, yet clinical guidelines lack recommendations for AF screening in this population. To identify and review current guidelines/policies for AF and RHD to assess whether recommendations are made for AF screening in patients with RHD, thereby identifying any policy gaps. A narrative policy content review was conducted. This included: guidelines, consensus statements, position statements and policy documents regarding AF or RHD. Documents were identified through searches in MEDLINE, national/international cardiovascular society websites and citation tracking. A narrative synthesis approach was used to review content. A total of 29 documents were identified (16 focussed on AF; 13 on RHD). Of the 16 AF-focussed documents, 13 recommended AF screening in the general population in high-risk groups, based on age and comorbidities. Only one, the 2021 Asia Pacific Heart Rhythm Society (APHRS) AF practice guidance, explicitly recommended AF screening in higher-risk patients with RHD. The 13 RHD-focussed documents acknowledged AF as a frequent complication, particularly in advanced valvular disease, but none specifically recommended screening. This review highlights a clear gap in current guidelines and policies for AF screening in those with RHD. Although AF is a common complication of RHD, only one policy document was identified that provided specific recommendations for AF screening in patients with RHD. Further work is needed to inform and develop appropriate AF screening guidelines tailored to RHD populations in different settings.

  • National Funding for Cardiac Arrest Research in Australia: An Analysis of Competitive Grant Schemes

    by Samuel Pointon, Jodie Ingles, Sue Timbs, Jamie Vandenberg, Janet Bray, Gregory Page, Garry Jennings, Andre La Gerche, Elizabeth D. Paratz

  • Open Access

    Multiday rhythms modulate human heart rate: an observational study in healthy adults

    by Rochelle I. De Silva, Rachel E. Stirling, Jodie Naim-Feil, Shivam Puri, Elizabeth Paratz, Philippa J. Karoly

    Background: Chronobiology research has historically focused on circadian rhythms; however, longer infradian rhythms are prevalent in human physiology and may have important implications for health and wellbeing. Previous studies have identified widespread infradian rhythms across human physiology, often in the context of hormonal regulation and disease. Despite growing evidence of their ubiquity, the mechanisms, significance, and clinical relevance of these rhythms remain poorly understood, largely due to lack of longitudinal datasets and robust detection methods. The emergence of new wearable technologies enables rich, continuous data capture within individuals, allowing physiological rhythms to be studied at scale. Methods: This study analyzed a cohort of healthy, young adults (N=623), with up to four years of wearable and questionnaire data collected through the University of Notre Dame’s (USA) NetHealth project. Participants who recorded at least three months of continuous (>80% adherence) heart rate data were included and significant infradian rhythms were identified using wavelet analysis. Unsupervised non-negative matrix factorization was performed to cluster similar wavelet power spectrum distributions. Individuals’ heart rate rhythms were compared to known environmental cycles (day-of-week, lunar, seasonal) and considering demographics and social networks. A second, smaller cohort (N=70) with heart rate and menstrual timing were included to analyze the interplay of hormonal regulation on monthly cycles. Multinomial logistic regression, and statistical tests (i.e., one-way ANOVA) were applied to quantify the effects of environmental, behavioral and demographic factors on heart rate rhythms. Findings: Significant infradian rhythms of heart rate were detected in 69.7% (365/523) of the cohort and 35.9% (188/523) had two or more rhythms. Annual, biannual and 10-week rhythms were the most common. Within the 4–45-day band, individuals clustered into four multiday chronotypes based on dominant periodicities in their wavelet power spectra: weekly (∼7 days), shorter-monthly (∼25 days), longer-monthly (∼35 days), and multi-month (>35 days). Heart rate rhythms were influenced by environmental cycles (day-of-week and seasonality) but were not tightly correlated to external cues. Additionally, heart rate rhythms were synchronized to the menstrual cycle in most menstruating females, although monthly rhythms were also observed in males and menopausal women. Interpretation: The prevalence of infradian, or multiday heart rate rhythms in healthy young people motivates further scientific investigation to understand the mechanisms of these rhythms and their potential association with autonomic function, and risk of disease or disease-specific symptoms. Characterizing physiological rhythms can drive new insights into how multiscale fluctuations modulate disease symptoms across neurological, psychiatric, and broader health conditions.


  • Open Access

    Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM

    by Ozlem Bilen, Arnon Adler, Rachel Bastiaenen, James P. MacNamara, Elizabeth Paratz, Elad Maor, Michael Arad, Matthew Gold, Nirav Patel, Cliff Pruett, et al.

    BACKGROUND: Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II–III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy). METHODS: Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for inclusion if they had ≥1 mavacamten prescription after the date of diagnosis. Patients were categorized based on background therapy status during mavacamten treatment: mavacamten monotherapy or mavacamten with background therapy (down-titration or no dose modification). RESULTS: Overall, 278 patients were included and received mavacamten (mavacamten monotherapy, n=88; mavacamten with background therapy, n=190). At month 9, most patients achieved ≥1 New York Heart Association class improvement from baseline (mavacamten monotherapy, 60.0%; mavacamten with background therapy, 61.0%). Improvements in resting and Valsalva left ventricular outflow tract gradients from baseline to month 9 were observed in both subgroups; mean left ventricular ejection fraction through month 9 remained ≥62.0% with mavacamten monotherapy and ≥61.4% with mavacamten with background therapy. Two patients in the mavacamten monotherapy subgroup and 1 patient in the mavacamten with background therapy subgroup permanently discontinued treatment owing to left ventricular ejection fraction <50%. CONCLUSIONS: Mavacamten monotherapy was associated with improvements in cardiac function and symptoms, and positive benefits to the risk profile over a 9-month follow-up period; this was consistent with improvements observed in patients treated with mavacamten with background therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06372457.


  • Open Access

    CSANZ and ACRA Position Statement on Quality Use of Telehealth in Cardiovascular Care

    by Susie Cartledge, Jonathan C. Rawstorn, Carmel Bourne, Carolyn M. Astley, Heena Akbar, Kimberley Bardsley, Nicole K. Bart, Andrea Driscoll, Rebecca Eddington, Andrew Goodman, et al.